secwatch.observer — SEC 8-K summary
======================================

Issuer:     Virpax Pharmaceuticals, Inc. (—)
CIK:        0001708331
Form:       8-K
Filed at:   2024-10-03T23:59:59+00:00
Accession:  0001731122-24-001539
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Virpax appoints board member Katharyn Field as Vice President and principal executive officer
--------------------------------------------------------------------------------

- Katharyn Field appointed VP and principal executive officer effective Sept. 27, 2024.
- Field will continue to serve as a member of the Board of Directors.
- Company is an emerging growth company; no prior CEO departure noted.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1708331/000173112224001539/0001731122-24-001539-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1708331/000173112224001539/e6005_8-k.htm
  HTML page:      https://secwatch.observer/filing/0001731122-24-001539

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer